Literature DB >> 32127645

The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer.

Xiaochen Liu1, Jianfeng Cui2, Li Gong1, Fei Tian1, Yangli Shen1, Lipeng Chen2, Yong Wang2, Yangyang Xia2, Lei Liu2, Xiang Ye1, Molin Wang1, Guangyi Liu3, Baichun Jiang1, Changshun Shao4, Yongxin Zou5, Yaoqin Gong6.   

Abstract

CUL4B, which acts as a scaffold protein in CUL4B-RING ubiquitin ligase (CRL4B) complexes, participates in a variety of biological processes. Previous studies have shown that CUL4B is often overexpressed and exhibits oncogenic activities in a variety of solid tumors. However, the roles and the underlying mechanisms of CUL4B in bladder cancer (BC) were poorly understood. Here, we showed that CUL4B levels were overexpressed and positively correlated with the malignancy of BC, and CUL4B could confer BC cells increased motility, invasiveness, stemness, and chemoresistance. The PIK3CA/AKT pathway was identified as a critical downstream mediator of CUL4B-driven oncogenicity in BC cells. Furthermore, we demonstrated that CRL4B epigenetically repressed the transcription of miR-372/373, via catalyzing monoubiquitination of H2AK119 at the gene cluster encoding miR-372/373, leading to upregulation of PIK3CA and activation of AKT. Our findings thus establish a critical role for the CUL4B-miR-372/373-PIK3CA/AKT axis in the pathogenesis of BC and have important prognostic and therapeutic implications in BC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32127645     DOI: 10.1038/s41388-020-1236-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 3.  Bladder cancer.

Authors:  Oner Sanli; Jakub Dobruch; Margaret A Knowles; Maximilian Burger; Mehrdad Alemozaffar; Matthew E Nielsen; Yair Lotan
Journal:  Nat Rev Dis Primers       Date:  2017-04-13       Impact factor: 52.329

Review 4.  The PI3K/AKT Pathway as a Target for Cancer Treatment.

Authors:  Ingrid A Mayer; Carlos L Arteaga
Journal:  Annu Rev Med       Date:  2015-10-14       Impact factor: 13.739

Review 5.  Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Authors:  Woonyoung Choi; Andrea Ochoa; David J McConkey; Mattias Aine; Mattias Höglund; William Y Kim; Francisco X Real; Anne E Kiltie; Ian Milsom; Lars Dyrskjøt; Seth P Lerner
Journal:  Eur Urol       Date:  2017-03-30       Impact factor: 20.096

6.  PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.

Authors:  M Cecilia Caino; Jagadish C Ghosh; Young Chan Chae; Valentina Vaira; Dayana B Rivadeneira; Alice Faversani; Paolo Rampini; Andrew V Kossenkov; Katherine M Aird; Rugang Zhang; Marie R Webster; Ashani T Weeraratna; Silvano Bosari; Lucia R Languino; Dario C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 7.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 8.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

Review 9.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 10.  Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.

Authors:  Felix A Mensah; Jean-Pierre Blaize; Locke J Bryan
Journal:  Onco Targets Ther       Date:  2018-08-13       Impact factor: 4.147

View more
  7 in total

1.  CUL4B Upregulates RUNX2 to Promote the Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Epigenetically Repressing the Expression of miR-320c and miR-372/373-3p.

Authors:  Jun Mi; Shuangshuang Wang; Panpan Liu; Chang Liu; Dexuan Zhuang; Xue Leng; Qun Zhang; Fuxiang Bai; Qiang Feng; Xunwei Wu
Journal:  Front Cell Dev Biol       Date:  2022-06-16

2.  Identification of different proteins binding to Na, K-ATPase α1 in LPS-induced ARDS cell model by proteomic analysis.

Authors:  Xu-Peng Wen; Guo Long; Yue-Zhong Zhang; He Huang; Tao-Hua Liu; Qi-Quan Wan
Journal:  Proteome Sci       Date:  2022-06-09       Impact factor: 2.882

3.  Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients.

Authors:  Hadi Ghasemi; Seyed Habibollah Mousavibahar; Mohammad Hashemnia; Jamshid Karimi; Iraj Khodadadi; Heidar Tavilani
Journal:  Mol Biol Rep       Date:  2021-06-04       Impact factor: 2.316

4.  KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.

Authors:  Lei Liu; Jianfeng Cui; Yajing Zhao; Xiaochen Liu; Lipeng Chen; Yangyang Xia; Yong Wang; Shouzhen Chen; Shuna Sun; Benkang Shi; Yongxin Zou
Journal:  Mol Cancer       Date:  2021-05-18       Impact factor: 27.401

5.  CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription.

Authors:  Xiang Ye; Xiaochen Liu; Min Gao; Li Gong; Fei Tian; Yangli Shen; Huili Hu; Gongping Sun; Yongxin Zou; Yaoqin Gong
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

6.  Comprehensive analysis of N6-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.

Authors:  Jianfeng Cui; Yaofeng Zhu; Xiaochen Liu; Wenfu Wang; Xuewen Jiang; Yangyang Xia; Guanwen Zhou; Shouzhen Chen; Benkang Shi
Journal:  Cancer Cell Int       Date:  2022-02-11       Impact factor: 5.722

7.  Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Weiwei Liu; Lu Zheng; Rongguiyi Zhang; Ping Hou; Jiakun Wang; Linquan Wu; Jing Li
Journal:  Mol Cancer       Date:  2022-03-11       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.